FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to the pharmaceutical industry, namely to a drug for the treatment of bacterial infections. The drug is proposed for the treatment of bacterial infections caused by bacteria selected from Mycobacterium tuberculosis, Streptococcus pyogenes, Salmonella enteritidis, Escherichia coli, Klebsiella pneumoniae, Chlamydophila pneumonia, as well as Klebsiella pneumoniae bacteria resistant to amoxicillin and clavulanic acid, Salmonella enterica bacteria resistant to streptomycin and nalidixic acid. The drug is a mixture including, in the effective amount in the form of decimal and centesimal dilutions, in the ratio of 1:1, 1:2, or 2:3, a product of technological treatment by a method for sequential multiple dilutions of initial substances of antibodies to β1 – a domain of a molecule of the main complex of histocompatibility of class 2 (HLA-DRB1), and a product of technological treatment by a method for sequential multiple dilutions of initial substance of antibodies to β2-microglobulin (β2-MG). In this case, the product of technological treatment by the method for sequential multiple dilutions of initial substance of antibodies is an aqueous or aqueous-alcohol solution obtained by multiple sequential dilution of a matrix initial solution of antibodies in combination with external mechanical impact – multiple shaking of each dilution, while a concentration of antibodies of 0.5÷5.0 mg/ml is used as the matrix solution.
EFFECT: invention provides for effective treatment of bacterial infections, reduction in antibiotic resistance, increase in the efficiency of therapeutic effect of antibiotics, including relatively to resistant bacteria.
9 cl, 2 tbl, 4 ex, 5 dwg
